Cambrex today announced that it had been recognized across six categories in the annual CMO (Contract Manufacturing Organization) Leadership Awards.
Sun Chemical released its Winter 2021 Regulatory Newsletter for customers which is available for download at www.sunchemical.com/sustainability/regulatory-newsletters.
Archroma, a global leader in specialty chemicals towards sustainable solutions, today announced a strategic partnership with technology innovator CleanKore, aiming to advance sustainable dyeing processes throughout the denim supply chain.
Lonza (with the Specialty Ingredients segment – LSI – reported as discontinued operations) today reported strong sales of CHF 4.5 billion, sales growth of 12.0%5, and CHF 1.4 billion CORE EBITDA, resulting in a margin of 31.2%. The results mainly reflect the Pharma Biotech & Nutrition segment (LPBN), which delivered 12.2%5 sales growth and a CORE EBITDA margin of 32.1%.
SOCMA has identified two EOs that will intersect with the work and activities of its Environmental, Health and Safety committee. Alongside our members, we are prepared to further our advocacy efforts through each agency's review and decision process.
In recognition of their tireless work during an incredibly challenging year, Pilot Chemical Corp. is awarding bonuses to each of its 400-plus employees at all operations in the U.S. and Mexico.
Jennifer Abril, President & CEO of the Society of Chemical Manufacturers & Affiliates (SOCMA), released a statement today in response to the inauguration of President Joseph R. Biden Jr. and Vice President Kamala Harris.
The Society of Chemical Manufacturers & Affiliates (SOCMA) is pleased to announce the addition of three companies – Valysynthese, Gold Eagle and Forever Pumpkin – to its growing and diverse membership. This brings SOCMA’s total membership to 135 companies to commence 2021.
Strem Chemicals, Inc. Licenses New Class of Air-Stable Ni(0) Pre-Catalysts from Max-Planck-Institut für Kohlenforschung
STREM Chemicals, Inc. has licensed a technology based on recent developments in the field of Ni(0) (pre)catalysts from the Max-Planck-Institut für Kohlenforschung respectively the associated Studiengesellschaft Kohle mbH.
Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
Capricor Therapeutics, a clinical-stage biotechnology company focused on the development of the first-in-class cell and exosome-based therapeutics for the treatment and prevention of serious diseases, and Lonza today announced that the companies have entered into an agreement for the development of CAP-1002, Capricor's leading clinical asset using allogeneic cardiosphere-derived cells (CDC) technology for the treatment of Duchenne Muscular Dystrophy (DMD) and complications arising from COVID-19.